Total Funding
1
8
Total FundingPost-IPO Equity raised
Growth Score
0 pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
881558
Epirus Biopharmaceuticals develops biosimilar monoclonal antibodies and therapeutic proteins for emerging markets.
Michael Wyand: Senior Vice President of Clinical and RegulatoryPast Role: Epirus Biopharmaceuticals, President & COO
Suman Patel: Vice President of Manufacturing and QualityPast Role: Biogen, Senior Diretcor
About the Company
EPIRUS is focusing on the central development of a broad pipeline of biosimilar monoclonal antibodies and therapeutic proteins, optimized for use within the SCALE™ disposable manufacturing system, and designed to be deployed in an "In Market, For Market" ™ manufacturing configuration.
